SEATTLE–(BUSINESS WIRE)–Apr. 20, 2016– Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced, in partnership with its collaborators, early clinical data from two oral presentations for two product candidates at the American Association for Cancer Research …